Evidence Table D-46. Sedation outcomes for studies comparing interventions to treat delirium: single arm studies

| Author, year | Study design | Population | Intervention group, n | Route of administration | Outcome definition | n / N (%), intervention group | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Breitbart, 2002[23](#_ENREF_23) | Cohort w/o comparison group | Cancer patients | Olanzapine (Mean dose: 3.0 Dose range: 2.5 to 10mg) | Oral | Not applicable | (30%) | |
| Breitbart, 2002[23](#_ENREF_23) | Cohort w/o comparison group | Cancer patients | Olanzapine (Mean dose: 3.0 Dose range: 2.5 to 10mg) | Oral | Not applicable | | (30%) |
| Breitbart, 2002[23](#_ENREF_23) | Cohort w/o comparison group | Cancer patients | Olanzapine (Mean dose: 3.0 Dose range: 2.5 to 10mg), 79 | Oral | Dosage reduced due to sedation | | 8 / 79 (10%) |
| Horikawa, 2003[34](#_ENREF_34) | Cohort w/o comparison group | Medical and surgical inpatients | Risperidone (Planned dose: 0.5 Max dose: 1.7mg), 10 | Oral | Daytime sleepiness | 3 / 10 (30%) | |
| Ikezawa, 2008[37](#_ENREF_37) | Open-label trial | Elderly patients with hyperactive-hypervalent delirium | Risperidone (Mean dose: 1.5 (0.7) Dose range: 0.5-3mg), 22 | Oral | Somnolence | | 4 / 22 (18%) |
| Kim, 2001[39](#_ENREF_39) | Open label study | Medico-surgical patients from Neurology, Neurosurgery and BMT unit | Olanzapine (Mean dose: 5.9 (1.5) Max dose: 8.8 (2.2), 20 | Oral | Mild sedation | | 2 / 20 (10%) |
| Kim, 2003[40](#_ENREF_40) | Cohort w/o comparison group | Patients in the acute medical units | Quetiapine (Planned dose: 25 Mean dose: 93.75mg), 12 | Not reported | Not applicable | 2 / 12 (17%) | |
| Kishi, 2012[43](#_ENREF_43) | Cohort w/o comparison group | Delirious cancer patients | Risperidone (Mean dose: 1.4mg), 29 | Oral | Mild sedation | 0 / 29 (0%) | |
| Maneeton, 2007[48](#_ENREF_48) | Open-label study | All physically ill in-patients whose pcp consulted psychiatrists | Quetiapine (Mean dose: 45.7 (28.7) Max dose: 100 Dose range: 25-100mg), 17 | Oral | Daytime sleepiness | 13 / 17 (76%) | |
| Mittal, 2004[50](#_ENREF_50) | Cohort w/o comparison group | Hospitalized patients | Risperidone (Mean dose: 0.75mg), 10 | Not reported | Mild sedation | 2 / 10 (20%) | |

| Author, year | Study design | Population | Intervention group, n | Route of administration | Outcome definition | n / N (%), intervention group |
| --- | --- | --- | --- | --- | --- | --- |
| Omura, 2003[52](#_ENREF_52) | Cohort w/o comparison group | Hospitalized patients | Quetiapine (Mean dose: 54.7 Dose range: 25 to 125mg), 24 | Not reported | Somnolence | 3 / 24 (13%) |
| Omura, 2003[52](#_ENREF_52) | Cohort w/o comparison group | Hospitalized patients | Quetiapine (Mean dose: 54.7 Dose range: 25 to 125mg), 24 | Not reported | Oversedation | 0 / 24 (0%) |
| Pae, 2004[53](#_ENREF_53) | Cohort w/o comparison group | Delirious patients recruited from the departments of neurosurgery, orthopedic surgery, and oncology | Quetiapine (Mean dose: 127.1mg), 22 | Oral | Stopped medication due to sedation | 2 / 22 (9%) |
| Pae, 2004[53](#_ENREF_53) | Cohort w/o comparison group | Delirious patients recruited from the departments of neurosurgery, orthopedic surgery, and oncology | Quetiapine (Mean dose: 127.1mg), 22 | Oral | Mild sedation | 3 / 22 (14%) |
| Parellada, 2004[54](#_ENREF_54) | Cohort w/o comparison group | General hospital patients | Risperidone (Mean dose: day 1, 2.6; day 3, 2.6; day 7, 1.5mg), 64 | Oral | Drowsiness | 2 / 64 (3%) |
| Sasaki, 2003[55](#_ENREF_55) | Cohort w/o comparison group | Inpatients and outpatients | Quetiapine (Mean dose: 44.9 Max dose: 63.5mg), 12 | Oral | Excessive sedation or somnolence in the daytime | 0 / 12 (0%) |
| Toda, 2005[60](#_ENREF_60) | Cohort w/o comparison group | Hospital patients with delirium | Risperidone (Mean dose: 0.92 Max dose: 1.38), 10 | Oral | Somnolence | 2 / 10 (20%) |

BMT=bone marrow transplant; Mg=milligram; N=sample size